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a b s t r a c t
Background: Thioredoxin-1 (Trx-1) is an abundant 12.5 kDa redox protein expressed in almost all eukary-
otic cells that protect against thedevelopmentof heart failure andkidneydysfunction. PlasmaTrx-1 levels
are considered as a reliable marker for oxidative stress. However, it remains to be determined whether
plasma Trx-1 levels can predict cardiac prognosis in patients with chronic heart failure (CHF).
Methods and results: We measured plasma Trx-1 levels and urinary 2-microglobulin–creatinine ratio
(UBCR), amarker for renal tubular damage, in 156 consecutive patients with CHF and 17 control subjects.
The patientswere prospectively followed for amedian follow-upperiod of 627days and46 cardiac events
were observed. The patients with cardiac events had signiﬁcantly higher plasma Trx-1 levels and UBCR
levels than the cardiac event-free patients.Multivariate Coxproportional hazard analysis revealed that an
elevated Trx-1 level was independently associated with poor outcome in patients with CHF after adjust-
ment for confounding factors (hazard ratio, 1.74; 95% conﬁdence interval, 1.33–2.29; p<0.0001). UBCR
was increased with higher plasma Trx-1 levels. Kaplan–Meier analysis demonstrated that the highest
Trx-1 tertile was associated with the highest risk of cardiac events.
Conclusion: Plasma Trx-1 level was associatedwith renal tubular damage and cardiac prognosis, suggest-
ing that it could be a useful marker to identify patients at high risk for comorbid heart failure and renal
tubular damage.
© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.ntroduction
Heart failure is a major health problem with high mortality
hat continues to increase in prevalence [1–4]. The development
f heart failure is closely associated with progressive left ventri-
ular remodeling in response to oxidative stress [5]. The major
ource of excessive oxidative stress in heart failure is considered
o be increased intracellular levels of reactive oxygen species (ROS)
6].
Thioredoxin-1 (Trx-1) is an abundant 12.5 kDa cytosolic pro-
ein expressed in almost all eukaryotic cells and plays an important
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914-5087/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights rerole in redox signaling. Trx-1 contains a dithiol/disulﬁde motif in
the redox-active site and serves as an ROS scavenger [7,8]. Circu-
lating Trx-1 was reported to be closely associated with systemic
oxidative stress [9,10] and was used as a reliable oxidative stress
marker. However, it is not knownwhether plasma Trx-1 is a useful
prognostic marker of chronic heart failure (CHF).
Cardio-renal interactionwasevaluatedbecausekidneydysfunc-
tion is indicative of extremely poor prognosis in patients with CHF
[11,12]. Notably, oxidative stress is a common pathophysiological
factor in the development of cardiac and kidney dysfunction, and
experimental studies have demonstrated that Trx-1 inhibits oxida-
tive stress in both heart and kidney tissue [13,14]. We previously
reported that renal tubular damage, as well as glomerular damage,
is a risk factor for poor prognosis in patients with CHF [15]. Renal
tubular cells are located in the renal medulla, which is affected by
hypoxia. Thus, we hypothesized that plasma Trx-1 was associated























































The subjects’ baseline characteristics are presented in Table 1.
There were 96 patients with NYHA functional class II and 60
patients with class III or IV. Hypertension, diabetes mellitus, and
hyperlipidemia were identiﬁed in 101 (65%), 43 (28%), and 53
Table 1







Age, years 69±5 72±10 0.1638
Gender (men/women) 7/10 100/56 0.0646
NYHA functional class (II/III, IV) 96/60
Hypertension, n (%) 12 (71%) 101 (65%) 0.4240
Diabetes mellitus, n (%) 2 (17%) 43 (28%) 0.2778
Hyperlipidemia, n (%) 6 (35%) 53 (34%) 0.9685
Etiology
Ischemic heart disease, n (%) 41 (26%)
Nonischemic heart disease, n (%) 115 (74%)
Blood examination
Log10 BNP (pg/mL) 1.4±0.3 2.6±0.5 <0.0001
Log10 Trx-1 (ng/mL) 1.7±0.4 2.1±0.8 0.0445
Kidney function
eGFR (mL/min/1.73m2) 72±8 67±26 0.5411
Log10 UACR (mg/g) 1.2±0.9 1.5±0.6 0.1823
Log10 UBCR (g/g) 1.6±0.7 2.2±0.9 0.0445
Log10 NAG (U/g) 0.77±0.12 1.01±0.29 0.0139
Echocardiography
LVEDD (mm) 47±6 56±10 0.0155
LVEF (%) 70±6 49±17 0.0004
Medication
ACEIs and/or ARBs, n (%) 117 (75%)
-Blockers, n (%) 117 (75%)
Statin, n (%) 61 (39%)
Aldosterone blockers, n (%) 44 (28%)
Loop diuretics, n (%) 104 (67%)
Data are expressed as mean± SD, number (percentage).
ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II recepter54 Y. Otaki et al. / Journal of
The purpose of the present studywas to examinewhether Trx-1
ould predict cardiac prognosis in patients with CHF.
ethods
tudy subjects
This was a prospective study of 156 consecutive patients who
ere admitted to our hospital for diagnosis or treatment of CHF.
eventeen age-matched control subjects who had no heart dis-
ase were also entered. The diagnoses of CHF were made by
wo cardiologists who used the generally accepted Framingham
riteria, including a history of dyspnea and symptomatic exer-
ise intolerance, signs of pulmonary congestion, peripheral edema,
nd radiological or echocardiographic evidence of left ventricular
nlargement or dysfunction.
Transthoracic echocardiography was performed by physicians
howere blinded to the biochemical data. The diagnoses of hyper-
ension, diabetesmellitus, and hyperlipidemiawere established on
he basis of the patient’s medical records or history of currently or
reviously received medical therapy. Ten patients were excluded
rom the study due to acute coronary syndrome within 3 months
receding the admission, active hepatic disease, pulmonary dis-
ase, ormalignant disease. Demographic and clinical data including
ge, gender, New York Heart Association (NYHA) functional class,
ndmedications at dischargewere collected from hospital medical
ecords and patient interviews.
iochemical assays
Venous blood and urine samples were obtained in the early
orning within 24h of admission. Plasma Trx-1 was measured
ith human thioredoxin-1 enzyme-linked immunosorbent assay
ELISA) kits (Japan Institute for the Control of Aging, Nikken Seil
o., Ltd., Shizuoka, Japan). Brain natriuretic peptide (BNP) concen-
rations were measured using a commercially available speciﬁc
adioimmunoassay for human BNP (Shiono RIA BNP assay kit,
hionogi Co., Ltd., Tokyo, Japan) [16]. The estimated glomeru-
ar ﬁltration rate (GFR) was calculated using the modiﬁcation of
iet in renal disease (MDRD) equation with the Japanese coef-
cient as previously reported [17]. We quantitatively measured
rinary albumin by immunoturbidimetry in a single spot urine
pecimen collected in the early morning. Urinary albumin levels
ere corrected for urinary creatinine in a single manner to urinary
icroalbumin–creatinine ratio (UACR). Urinary 2-microglobulin
oncentration to creatinine ratio (UBCR), amarker for renal tubular
amage, was determined by the latex agglutination method (BML,
nc., Tokyo, Japan) [18]. N-acetyl--d-glucosaminidase (NAG), a
arker of early renal tubular damage, was measured in single
pot urine specimens. Because BNP, UACR, UBCR, NAG, and Trx-
were not normally distributed, we performed all analyses using
og-transformed values.
nd-points and follow-up
The patientswere prospectively followed for amedian period of
27 days (interquartile range, 406–896 days). All the patients were
ollowed by telephone interview or medical record review twice a
ear for 1250 days. The end points were cardiac death (deﬁned as
eath from progressive heart failure, acute coronary syndrome, or
udden cardiac death) and progressive heart failure requiring re-
ospitalization. Sudden cardiac deathwasdeﬁned as deathwithout
eﬁnitepremonitory symptomsor signs andwasestablishedby the
ttending physician.logy 64 (2014) 353–359
The study was approved by the institutional ethics committee,
and all the patients provided informed consent.
Statistics
All values are expressed as the mean± standard deviation
(SD). We employed t-tests, chi-square tests, and linear analy-
sis to compare continuous and categorical variables, respectively.
Kruskal–Wallis test was used to compare Trx-1 with NYHA func-
tional class. A Cox proportional hazard analysis was performed to
determine independent predictors for cardiac events. Signiﬁcant
predictors selected in the univariate analysis were entered into the
multivariate analysis. The receiver operating characteristics curve
of Trx-1 was constructed to determine the area under the curve
(AUC), sensitivity, and speciﬁcity. The AUC for cardiac events was
calculated by the trapezoidal rule. Proportionality in the Coxmodel
was evaluated with log-minus-log survival plots. A cardiac event-
free curve was constructed according to the Kaplan–Meier method
and comparedusing a log-rank test. Ap-value <0.05was considered
statistically signiﬁcant. Statistical analyses were performed with a
standard program package (JMP version 8; SAS Institute Inc., Cary,
NC, USA).
Results
Baseline patient characteristicsblockers; BNP, brain natriuretic peptide; eGFR, estimated glomerular ﬁltration rate;
LVEDD, left ventricular end diastolic dimension; LVEF, left ventricular ejection
fraction; NAG, N-acetyl--d-glucosaminidase; NYHA, New York Heart Association;
Trx-1, thioredoxin 1; UACR, urinary albumin to creatinine ratio; UBCR, urinary 2-
microglobulin to creatinine ratio.






















































































Age, years 71±10 73±11 0.4058
Gender (men/women) 67/43 33/13 0.1985
NYHA functional class (II/III, IV) 76/34 20/26 0.0027
Hypertension, n (%) 70 (64%) 31 (67%) 0.6544
Diabetes mellitus, n (%) 27 (25%) 16 (35%) 0.1920
Hyperlipidemia, n (%) 35 (32%) 18 (39%) 0.3792
Etiology 0.0058
Ischemic heart disease, n (%) 22 (20%) 19 (41%)
Non-ischemic heart disease, n (%) 88 (80%) 27 (59%)
Blood examination
Log10 BNP (pg/mL) 2.5±0.4 2.7±0.5 0.0206
Log10 Trx-1 (ng/mL) 1.9±0.7 2.6±0.8 <0.0001
Kidney function
eGFR (mL/min/1.73m2) 70±22 60±32 0.0270
Log10 UACR (mg/g) 1.3±0.6 1.8±0.6 0.0001
Log10 UBCR (g/g) 1.9±0.7 2.8±1.0 <0.0001
Log10 NAG (U/g) 0.97±0.28 1.14±0.32 0.0006
Echocardiography
LVEDD (mm) 55±9 57±10 0.5949
LVEF (%) 50±18 48±16 0.6385
Medication
ACEIs and/or ARBs, n (%) 83 (76%) 34 (74%) 0.8393
-Blockers, n (%) 77 (70%) 40 (87%) 0.0257
Statin, n (%) 42 (38%) 19 (41%) 0.7155
Aldosterone blockers, n (%) 32 (29%) 12 (26%) 0.7038
Loop diuretics, n (%) 65 (59%) 39 (85%) 0.0019
Data are expressed as mean± SD, number (percentage).
ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II recepter
blockers; BNP, brain natriuretic peptide; eGFR, estimated glomerular ﬁltration rate;
LVEDD, left ventricular end diastolic dimension; LVEF, left ventricular ejection
fraction; NAG, N-acetyl--d-glucosaminidase; NYHA, New York Heart Association;
Trx-1, thioredoxin 1; UACR, urinary albumin to creatinine ratio; UBCR, urinary 2-
microglobulin to creatinine ratio.
Table 3
Univariate and multivariate Cox proportional hazard analysis of predicting cardiac







Age (per 1 year increase) 1.02 0.98–1.06 0.2794
Gender (woman vs. man) 0.63 0.33–1.23 0.1786
NYHA functional class (III, IV vs. II) 2.66 1.46–4.85 0.0015
Hypertension 1.31 0.68–2.51 0.4187
Diabetes mellitus 1.95 1.06–3.57 0.0320
Hyperlipidemia 1.36 0.74–2.49 0.3246
Log10 BNP (per 1-SD increase) 1.51 1.07–4.54 0.0173
Log10 Trx-1 (per 1-SD increase) 1.69 1.36–2.10 <0.0001
eGFR (per 1-SD increase) 0.64 0.47–0.93 0.0157
Log10 UACR (per 1-SD increase) 1.90 1.44–2.52 <0.0001
Log10 UBCR (per 1-SD increase) 2.68 2.02–3.56 <0.0001
Log10 NAG (per 1-SD increase) 1.81 1.32–2.47 0.0002
LVEDD (per 1 SD increase) 1.16 0.84–1.61 0.3607
LVEF (per 1 SD increase) 0.89 0.84–1.51 0.4246
Multivariate analysis
NYHA functional class (III, IV vs. II) 1.85 0.98–3.47 0.0574
eGFR (per 1 SD increase) 0.77 0.53–1.08 0.1432
Log10 BNP (per 1 SD increase) 1.17 0.80–1.70 0.4154
Log10 Trx-1 (per 1 SD increase) 1.74 1.33–2.29 <0.0001
BNP, brain natriuretic peptide; eGFR, estimated glomerular ﬁltration rate; LVEDD,
left ventricular enddiastolicdimension; LVEF, left ventricular ejection fraction;NAG,
N-acetyl--d-glucosaminidase; NYHA, New York Heart Association; Trx-1, thiore-ig. 1. The association between Trx-1 and NYHA functional class. Trx-1 was
ncreased with advancing NYHA functional class (Kruskal–Wallis test, p=0.0432).
YHA, New York Heart Association; Trx-1, thioredoxin-1.
34%) patients with CHF, respectively. Heart failure etiologies were
dentiﬁed as ischemic heart disease (IHD) in 41 (26%) patients
nd non-IHD in 115 (74%) patients. The mean log10 Trx-1 value
as 2.1±0.8ng/mL. Plasma Trx-1 levels increased with advancing
YHA functional class (Fig. 1).
ssociation of plasma Trx-1 and renal tubular damage markers
To investigate the relationship between plasma Trx-1 and renal
ubular damage, we preformed simple linear analysis. There was
igniﬁcant correlation between plasma Trx-1 and renal tubu-
ar damage markers (UBCR: r=0.169, p=0.0347; NAG: r=0.172,
= 0.0324, respectively). Also, log10 UACR correlated to plasmaTrx-
(UACR: r=0.178, p=0.0267). On the other hand, there was no
igniﬁcant correlation between plasma Trx-1 and other parame-
ers including age, log10 BNP, estimated glomerular ﬁltration rate
eGFR), left ventricular end diastolic diameter, and left ventricular
jection fraction.
omparison of clinical characteristics between patients with and
ithout cardiac events
There were 46 cardiac events (29% of patients) during the
ollow-up period, including eight cardiac deaths and 38 re-
ospitalizations for worsening heart failure. The causes of cardiac
eath were worsening CHF in ﬁve patients, ventricular ﬁbrillation
n one patient, acute coronary syndrome in one patient, and sudden
ardiac death in one patient.
As shown in Table 2, patients who experienced cardiac events
ere in a more severe NYHA functional class than those who
id not. Patients with cardiac events showed a higher prevalence
f IHD; higher log10 BNP, log10 Trx-1, log10 UACR, log10 UBCR, and
og10 NAG; and lower eGFR compared to those without. Patients
ith cardiac events took more -blockers and diuretics than those
ho did not experience events. There were no signiﬁcant differ-
nces between the two groups in age, gender, prevalence rates of
ypertension, diabetes mellitus, and hyperlipidemia, and echocar-
iographic parameters.
rx-1 and clinical outcomes
We performed univariate and multivariate Cox proportional
azard regression analyses to identify risk factors for cardiac events
Table 3). In the univariate analysis, Trx-1 was signiﬁcantly asso-
iated with cardiac events. Furthermore, NYHA functional class,
iabetes mellitus, eGFR, log10 BNP, log10 UACR, log10 UBCR, and
og10 NAG were signiﬁcantly related to cardiac event occurrence.
he multivariate analysis revealed that Trx-1 was an independent
doxin 1; UACR, urinary albumin to creatinine ratio; UBCR, urinary2-microglobulin
to creatinine ratio.













Hazard ratio (95%CI) P value
1.24 (0.66 – 2.31)
1.61 (1.07 – 2.41)
2.19 (1.58 – 3.02)
1.80 (1.26 – 2.58)







2.25 (1.53 – 3.31)
0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
Fig. 2. Univariate analysis of plasma Trx-1 to predict future cardiac events in the
settings of IHD, non-IHD, heart failure with preserved ejection fraction (HFpEF:
left ventricular ejection fraction>50%), heart failure with reduced ejection frac-
tion (HFrEF: left ventricular ejection fraction≤50%), elderly age (>65 years old), and
young age (≤65 years old). Plasma Trx-1 was signiﬁcantly related to cardiac events


































addition to severe HF. Furthermore, high Trx-1+high UBCR grouplasma Trx-1 was not related to future cardiac events in young patients with CHF.
rx-1, thioredoxin-1; IHD, ischemic heart disease.
redictor for cardiac events after adjustment of NYHA functional
lass, eGFR, and log10 BNP (Trx-1, hazard ratio 1.74; 95% conﬁdence
nterval, 1.33–2.29, p<0.0001) (Table 3).
Subgroups analyses were performed in the setting of IHD,
on-IHD, HF with reduced ejection fraction (HFrEF: left ventri-
ular ejection fraction≤50%), HF with preserved ejection fraction
HFpEF: left ventricular ejection fraction>50%), elderly age (>65
ears old), and young age (≤65 years old). Patients with IHD had
igher plasma Trx-1 than non-IHD patients (2.3±0.9 vs. 2.0±0.8,
= 0.0211). On the other hand, there was no signiﬁcant difference
nplasmaTrx-1 level betweenHFrEF andHFpEF andelderly age and
oungage.As shown inFig. 2, plasmaTrx-1was signiﬁcantly related
o future cardiac events in patients with IHD, non-IHD, HFpEF,
FrEF, and elderly age. However, plasma Trx-1 was not associated
ith cardiac events in young patients with CHF.
rx-1 and risk stratiﬁcation
The patients were divided into three groups based on the
rx-1 levels: ﬁrst tertile (≤1.6ng/mL), n=52; second tertile
1.6–2.4ng/mL), n=52; and third tertile (>2.4ng/mL), n=52. Third
ertile patients exhibited a higher mean log10 UBCR compared to
hose in the ﬁrst tertile (Fig. 3A). Similarly, second and third ter-
ile patients showed higher levels of log10 NAG than those in the
rst tertile (Fig. 3B). On the other hand, there were no signiﬁcant
ifferences in glomerular damage as assessed by log10 UACR and
GFR (Fig. 3C and D). The risk ratios were 1.0, 2.9, and 5.2 for the
rst to third tertiles, respectively (Fig. 4A). Kaplan–Meier analysis
emonstrated that the third tertile had the highest rate of cardiac
vents among the three groups (Fig. 4B).
omparison of Trx-1 and BNP prognostic values
The receiver operating characteristics curve was constructed to
etermine the optimal cut-off value, sensitivity, and speciﬁcity of
rx-1. The AUC, sensitivity, and speciﬁcity were 0.74, 70%, and 71%,
espectively. Interestingly, the AUC of Trx-1 was larger than that of
NP (Fig. 5).logy 64 (2014) 353–359
Combination of plasma Trx-1 and UBCR
We divided all CHF patients into three groups based on the
abnormal level of UBCR (UBCR≥300g/g) and abnormal level of
plasmaTrx-1 (log10 Trx-1 >2.2ng/mL): (1) normal group,n=70; (2)
high Trx-1 or high UBCR group, n=61; and (3) high Trx-1+high
UBCR group, n=25. The Kaplan–Meier analysis demonstrated that
high Trx-1+high UBCR group had the greatest risk in patients with
CHF (Fig. 6).
Discussion
The results of this study yielded several novel ﬁndings: (1)
Trx-1 was increased with advancing HF; (2) patients with cardiac
events had higher levels of plasma Trx-1 than those without it;
(3) multivariate Cox proportional hazard analysis demonstrated
that Trx-1 was an independent predictor of cardiac events; (4)
patientswith elevatedplasmaTrx-1hadhigher levels of renal tubu-
lar damagemarkers, such as log10 UBCR and log10 NAG; and (5) the
Kaplan–Meier analysis revealed that the risk of cardiac events was
greatest in the highest Trx-1 tertile.
Oxidative stress and heart failure
Oxidative stress has garnered much interest for its role in CHF
development [19,20]. It is associated with apoptosis or necrosis
in cardiomyocytes, extracellular matrix remodeling, and contrac-
tile and endothelial dysfunction with resultant cardiac remodeling
in the failing heart [21]. Trx-1 was reported to reduce intracellu-
lar ROS generation and subsequent cardiac cell loss in response to
ROS [22]. Experimental studies indicated that Trx-1 overexpression
protects against cardiac cell apoptosis and is associated with good
cardiac function in animalmodels of HF [14,23]. Trx-1 is reportedly
rapidly released into the circulation from the damaged cardiomy-
ocytes [24,25], and is increased with advancing CHF severity [9].
Here we showed for the ﬁrst time that plasma Trx-1 is an inde-
pendent predictor of future cardiac events. The receiver operating
characteristics curve analysis demonstrated that the AUCof plasma
Trx-1 was greater than that of BNP. Multivariate Cox proportional
hazard regression analysis revealed that plasma Trx-1was an inde-
pendent predictor of future cardiac events, even after adjustment
for BNP in patients with CHF. Therefore, plasma Trx-1 can provide
additional clinical information to BNP values and may serve as a
marker to stratify CHF patients by risk.
Oxidative stress in CHF and kidney dysfunction
Oxidative stress is a pathophysiological process fundamental to
both HF and kidney dysfunction. It was reported that urinary 8-
hydroxy-2′-deoxyguanosine, also a useful oxidative stress marker,
is not related to eGFR [26]. Similarly, therewas no signiﬁcant differ-
ence in glomerular damage markers, such as eGFR and log10 UACR,
in patients in different Trx-1 tertiles. However, patients with high
Trx-1valueshadhigherUBCRandNAGvalues, suggesting that renal
tubular damage was associated with oxidative stress in patients
with CHF. We previously reported that renal tubular damage is
also a risk factor for cardiac events in patients with CHF as well
as glomerular damage [15,27,28]. Renal tubular damage was rec-
ognizedas aﬁnal commonpathway for end-stage renal dysfunction
[29,30]. Thus, patients with high plasma Trx-1 may have poor car-
diac prognosis due to the development of kidney dysfunction inhad thegreatest risk inpatientswithCHF, suggesting that combined
measurement of plasma Trx-1 and UBCR could be a highly reliable
evaluation for risk-stratifying patientswith CHF. Our results clearly


























































































































Thioredoxin-1 level Thioredoxin-1 level
Not significant(C) (D)
Fig. 3. (A) The association between plasma Trx-1 and log10 UBCR. The third tertile of plasma Trx-1 had higher levels of log10 UBCR compared to the ﬁrst tertile (p=0.0301). (B)
The association between plasma Trx-1 and log10 NAG. The second and third tertiles of plasma Trx-1 had higher levels of log10 NAG than the ﬁrst tertile (third tertile, p=0.0099;
second tertile,p=0.0114). (C) TheassociationbetweenplasmaTrx-1 and log10 UACR. (D) TheassociationbetweenplasmaTrx-1 andeGFR. eGFR, estimatedglomerularﬁltration
rate; NAG, N-acetyl--d-glucosaminidase; Trx-1, thioredoxin-1; UACR, urinary microalbumin–creatinine ratio; UBCR, urinary 2-microglobulin concentration to creatinine
ratio.
Fig. 4. (A) Cox proportional hazard regression analysis. Hazard ratio relative to the ﬁrst tertile. *p<0.05 vs. ﬁrst tertile. (B) Kaplan–Meier analysis of all cardiac events in
patients in the three groups based on thioredoxin-1 level.








The cut-off value of log10 Trx-1 = 2.2 ng/ml
Area under the curve = 0.74










The cut-off value of log10 BNP = 2.75  ng/ml
Area under the curve = 0.63
Sensitivity = 54%, Specificity = 75%
Fig. 5. The receiver operating characteristics curveof Trx-1 for future cardiac events.
The area under the curve, sensitivity, and speciﬁcity of Trx-1 were 0.72, 68%, and
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Sugiyama S, Yoshimura M, Yasue H, Nakamura H, Yodoi J, Ogawa H. Increasedad the greatest risk in patients with chronic heart failure. Trx-1, thioredoxin-1;
BCR, urinary 2-microglobulin concentration to creatinine ratio.
dentify plasma Trx-1 as a usefulmarker to identify patients at high
isk for the related comorbidities of HF and renal tubular damage.
imitations
First,wewere unable to conﬁrm theprecisemechanismof Trx-1
ecretion in this prospective observational study. Second, since this
tudy performed one-time measurement of plasma Trx-1, serial
hanges in plasma Trx-1 in response to symptom improvement
ere not conﬁrmed. Third, the study number was relatively small.
study using a greater number of patients is needed to determine
he prognostic value of plasma Trx-1. Finally, in the present study,
ptimal medical therapy was independently administered based
n symptom improvements, physical examination, and chest X-
ay ﬁndings by the physicians who were blinded to the results of
he biochemical analyses. Thus, -blocker was properly adminis-
ered to patients with severe CHF. Thismay contribute to the result
hat patients with cardiac events took more -blocker than those
ithout it.
onclusion
Plasma Trx-1 level was associated with renal tubular damage
nd was predictive of cardiac prognosis. Plasma Trx-1 could be a
seful marker to identify patients at increased risk for comorbid
F and renal tubular damage.
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